An Open-label Extension of Study AC-066A301 Investigating the Safety and Tolerability of ACT-385781A in Patients With Pulmonary Arterial Hypertension (PAH)

Trial Profile

An Open-label Extension of Study AC-066A301 Investigating the Safety and Tolerability of ACT-385781A in Patients With Pulmonary Arterial Hypertension (PAH)

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Epoprostenol (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions
  • Acronyms Epitome2ext
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 14 Dec 2015 Status changed from active, no longer recruiting to completed, according to ClinilcaTrials.gov record.
    • 09 Apr 2015 Planned End Date changed from 1 Apr 2014 to 1 Jul 2015 as reported by ClinicalTrials.gov
    • 09 Apr 2015 Planned primary completion date changed from 1 Mar 2014 to 1 Jun 2015 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top